Patents by Inventor Steven Shoelson

Steven Shoelson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Reducing risk of type 2 diabetes (T2D)
    Patent number: 8445467
    Abstract: This invention relates to methods for reducing chronic subacute inflammatory states associated with obesity and improve glycemia, thereby preventing or delaying the development of type 2 diabetes (T2D) in obese subjects, or subjects with the metabolic syndrome, using non-acetylated forms of salicylate, e.g., salsalate or trilisate.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: May 21, 2013
    Assignee: Joslin Diabetes Center, Inc.
    Inventors: Steven Shoelson, Allison B. Goldfine
  • REGULATORY T CELLS IN ADIPOSE TISSUE
    Publication number: 20110044939
    Abstract: Methods of preventing, delaying, or reducing the development or severity of obesity-associated disorders, including administering Fat-specific regulatory T cells, or administering factors secreted by said T cells.
    Type: Application
    Filed: June 27, 2008
    Publication date: February 24, 2011
    Applicant: JOSLIN DIABETES CENTER, INC.
    Inventors: Markus Feuerer, Diane J. Mathis, Steven Shoelson, Christophe O. Benoist
  • TREATMENT OF CARDIOVASCULAR DISEASE WITH SALICYLATES
    Publication number: 20110021468
    Abstract: This invention relates to methods for the treatment of atherosclerotic cardiovascular disease using a non-acetylated forms of salicylate, e.g., salsalate and/or trilisate.
    Type: Application
    Filed: July 3, 2008
    Publication date: January 27, 2011
    Applicant: JOSLIN DIABETES CENTER, INC.
    Inventors: Steven Shoelson, Allison B. Goldfine
  • REDUCING RISK OF TYPE 2 DIABETES (T2D)
    Publication number: 20090298796
    Abstract: This invention relates to methods for reducing chronic subacute inflammatory states associated with obesity and improve glycemia, thereby preventing or delaying the development of type 2 diabetes (T2D) in obese subjects, or subjects with the metabolic syndrome, using non-acetylated forms of salicylate, e.g., salsalate or trilisate.
    Type: Application
    Filed: April 27, 2007
    Publication date: December 3, 2009
    Applicant: JOSLIN DIABETES CENTER, INC.
    Inventors: Steven Shoelson, Allison B. Goldfine
  • Method for identifying compounds for treatment of insulin resistance
    Patent number: 6630312
    Abstract: The invention features a method of identifying, evaluating or making a compound or agent, e.g., a candidate compound or agent, for treatment of a disorder characterized by insulin resistance. The method includes evaluating the ability of a compound or agent to bind IKK-&bgr; or modulate IKK-&bgr; activity, to thereby identify a compound or agent for the treatment of a disorder characterized by insulin resistance. The invention also features compounds for treating insulin resistance identified by such methods, and methods of treating a subject having a disorder characterized by insulin resistance by administering such agents.
    Type: Grant
    Filed: February 2, 2001
    Date of Patent: October 7, 2003
    Assignee: Joslin Diabetes Center, Inc.
    Inventor: Steven Shoelson
  • Methods for treatment of insulin resistance
    Publication number: 20030044852
    Abstract: The invention features a method of identifying, evaluating or making a compound or agent, e.g., a candidate compound or agent, for treatment of a disorder characterized by insulin resistance. The method includes evaluating the ability of a compound or agent to bind IKK-&bgr; or modulate IKK-&bgr; activity, to thereby identify a compound or agent for the treatment of a disorder characterized by insulin resistance. The invention also features compounds for treating insulin resistance identified by such methods, and methods of treating a subject having a disorder characterized by insulin resistance by administering such agents.
    Type: Application
    Filed: October 11, 2002
    Publication date: March 6, 2003
    Applicant: Joslin Diabetes Center, Inc., a Massachusetts corporation
    Inventor: Steven Shoelson
  • Method for identifying compounds for treatment of insulin resistance
    Patent number: 6468755
    Abstract: The invention features a method of identifying, evaluating or making a compound or agent, e.g., a candidate compound or agent, for treatment of a disorder characterized by insulin resistance. The method includes evaluating the ability of a compound or agent to interact with, e.g., bind, IKK-&bgr;, to thereby identify a compound or agent for the treatment of a disorder characterized by insulin resistance. The invention also features compounds for treating insulin resistance identified by such methods, and methods of treating a subject having a disorder characterized by insulin resistance by administering such agents.
    Type: Grant
    Filed: August 10, 2000
    Date of Patent: October 22, 2002
    Assignee: Joslin Diabetes Center, Inc.
    Inventor: Steven Shoelson
  • Method for identifying compounds for treatment of insulin resistance
    Publication number: 20010036625
    Abstract: The invention features a method of identifying, evaluating or making a compound or agent, e.g., a candidate compound or agent, for treatment of a disorder characterized by insulin resistance. The method includes evaluating the ability of a compound or agent to bind IKK-&bgr; or modulate IKK-&bgr; activity, to thereby identify a compound or agent for the treatment of a disorder characterized by insulin resistance. The invention also features compounds for treating insulin resistance identified by such methods, and methods of treating a subject having a disorder characterized by insulin resistance by administering such agents.
    Type: Application
    Filed: February 2, 2001
    Publication date: November 1, 2001
    Inventor: Steven Shoelson
  • Activated mutants of SH2-domain-containing protein tyrosine phosphatases and methods of use thereof
    Patent number: 6156551
    Abstract: The invention relates to novel mutant SH2 domain containing protein tyrosine phosphatases wherein the phosphatase is partially or constitutively active; and whose ability to regulate biological processes are different from the wildtype protein tyrosine phosphatases. The invention also relates to methods of use of the novel mutants, for example, in in vitro assays to screen for binding partners and inhibitors of protein tyrosine phosphatases and in the treatment of protein tyrosine phosphatase mediated diseases or conditions.
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: December 5, 2000
    Assignees: Beth Israel Deaconess Medical Center, Joslin Diabetes Center
    Inventors: Benjamin G. Neel, Alana M. O'Reilly, Steven Shoelson, Scott Pluskey
  • Inhibition of signal transduction molecules
    Patent number: 5801149
    Abstract: A peptide capable of inhibiting the interaction of an SH2 domain containing protein with a second protein.
    Type: Grant
    Filed: March 21, 1995
    Date of Patent: September 1, 1998
    Assignee: Joslin D-abetes Center, Inc.
    Inventor: Steven Shoelson